Aura Biosciences, Inc.
Aura Biosciences, Inc. (AURA): 2 pipeline candidates · 1 upcoming catalyst · ~10 mo cash runway · 10 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
9.6 months
D/E 0.28 · 5% dilution
Lead: Phase 3
2 candidates
1 upcoming, next in ~789d
0 buys · 9 sells (180d)
A transparent, data-derived signal for Aura Biosciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$646.2M
Cash
$85.6M
Quarterly Burn
$29.9M
Runway
9.6 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (2 candidates)
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
123
Total value held
$255.3M
| Holder | Shares | Value |
|---|---|---|
| matrix capital management company, lp | 6,922,870 | $46.3M |
| adage capital partners gp, l.l.c. | 4,881,125 | $32.7M |
| vanguard capital management llc | 4,487,656 | $30.0M |
| suvretta capital management, llc | 4,372,884 | $29.3M |
| blackrock, inc. | 3,586,640 | $24.0M |
| franklin resources inc | 2,072,726 | $13.9M |
| geode capital management, llc | 1,310,862 | $8.8M |
| millennium management llc | 1,097,627 | $7.3M |
| state street corp | 964,670 | $6.5M |
| levin capital strategies, l.p. | 941,400 | $6.3M |
Showing top 10 of 123 institutional holders of Aura Biosciences, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Aura Biosciences, Inc.'s pipeline?
Aura Biosciences, Inc. (AURA) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Aura Biosciences, Inc.'s lead drug candidate?
Aura Biosciences, Inc.'s most advanced tracked candidate is AU-011 (Phase 1) for Uveal Melanoma; Eye Cancer; Non-muscle-invasive Bladder Cancer.
What is Aura Biosciences, Inc.'s next catalyst?
Aura Biosciences, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotal" — expected August 15, 2028.
What is Aura Biosciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Aura Biosciences, Inc. has approximately 9.6 months of cash runway.
What is Aura Biosciences, Inc.'s market capitalization?
Aura Biosciences, Inc.'s market capitalization is approximately $646.2M.
Get the full picture on Aura Biosciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.